Home » USA Broker Ratings » DexCom, Inc. – Consenus Indicates Potential 5.1% Upside

DexCom, Inc. – Consenus Indicates Potential 5.1% Upside

DexCom, Inc. found using ticker (DXCM) now have 15 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 185 and 125 and has a mean target at 164.87. Given that the stocks previous close was at 156.87 this indicates there is a potential upside of 5.1%. The day 50 moving average is 150.03 while the 200 day moving average is 136.15. The company has a market capitalisation of $14,056m. Visit the company website at: http://www.dexcom.com

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.